Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2

Henry Pertinez, Rajith KR Rajoli, Saye H Khoo, Andrew Owen
doi: https://doi.org/10.1101/2021.01.03.21249159

Article Information

doi 
https://doi.org/10.1101/2021.01.03.21249159
History 
  • January 5, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Henry Pertinez1,2,
  2. Rajith KR Rajoli1,2,
  3. Saye H Khoo1,2 and
  4. Andrew Owen1,2,*
  1. 1Department of Pharmacology and Therapeutics, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  2. 2Centre of Excellence in Long acting Therapeutics (CELT), University of Liverpool, Liverpool, L69 3BX, UK
  1. ↵*Author for correspondence:
    Professor Andrew Owen, Department of Pharmacology and Therapeutics, Materials Innovation Factory, University of Liverpool, 51 Oxford Street, Liverpool L7 3NY, United Kingdom, Email - aowen{at}liverpool.ac.uk, Phone - +44 (0)151 795 7129
Back to top
Posted January 05, 2021.
Download PDF
Data/Code
Email
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5’-triphosphate exposure to support posology for SARS-CoV-2
Henry Pertinez, Rajith KR Rajoli, Saye H Khoo, Andrew Owen
medRxiv 2021.01.03.21249159; doi: https://doi.org/10.1101/2021.01.03.21249159
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area